-
Doxycycline Hyclate for BBB and MMP Research
2026-08-15
Doxycycline hyclate gives neurovascular researchers a practical pharmacological tool for testing how MMP activity contributes to blood-brain barrier failure, neuronal apoptosis, and cognitive dysfunction. This workflow translates a mouse arsenic-exposure study into coordinated permeability, tight-junction, enzymatic, and behavioral assays.
-
EZ Cap™ Firefly Luciferase mRNA Guide
2026-08-14
A scenario-based laboratory guide to using EZ Cap™ Firefly Luciferase mRNA (SKU R1018) in viability, proliferation, cytotoxicity, delivery, and reporter assays. It explains Cap1 biology, handling, controls, data interpretation, LNP-related variables, and practical product-selection criteria.
-
STING agonist-1: Assay Workflow Guide
2026-08-14
Build reproducible STING pathway experiments with a DMSO-soluble small molecule designed for innate immune activation. This guide connects concentration-response testing, type I interferon readouts, and the CD40–STING–TRAF2–IRF4 axis to practical cancer immunotherapy research while emphasizing controls and troubleshooting.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflows
2026-08-13
Build clearer mRNA delivery experiments by pairing direct Cy5 tracking with Firefly Luciferase expression in the same transcript. This workflow separates uptake, intracellular localization, and translation so researchers can optimize delivery materials, including peptide coacervates, with fewer ambiguous results.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-08-13
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG in ICC/IF, frozen and paraffin IHC, flow cytometry, and fluorescence-based ELISA workflows. It should be paired with validated goat IgG primary antibodies and should not be treated as a direct antigen probe or as a universal secondary for non-goat immunoglobulins.
-
CBD Mechanisms in Orofacial Inflammatory Pain
2026-08-12
A 2026 Brain Research Bulletin study shows that cannabidiol reduces inflammatory pain while also improving anxiety-like, depression-like, and cognitive abnormalities in mice. Its main innovation is the integration of peripheral CB2 signaling, central CB1-associated endocannabinoid changes, and serotonin dynamics in the central amygdala to explain both sensory and affective effects.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-12
Masitinib (AB1010) provides a DMSO-compatible approach for selective KIT and PDGFRα/β inhibition in cancer biology, mastocytosis research, and inflammatory disease models. It is not appropriate for workflows requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or direct clinical treatment conclusions.
-
MLN2238: Proteasome β5 Subunit Inhibitor
2026-08-11
MLN2238 is a reversible proteasome β5 subunit inhibitor with a product-reported β5 IC50 of 3.4 nM. It supports proteasome inhibition, apoptosis, proteotoxic-stress, multiple myeloma, and lymphoma research, but its β1 and β2 activity, solubility, and model-specific evidence require controlled experimental interpretation.
-
Temafloxacin Pharmacokinetics: Evidence and Implications
2026-08-11
Dudley’s review integrates human pharmacokinetic studies to show that temafloxacin combines high oral bioavailability, extensive tissue distribution, and a long elimination half-life that supports once- or twice-daily dosing. Its analysis also clarifies how renal function, elimination pathways, and drug-interaction data should inform dose selection, while highlighting why these findings cannot be transferred directly to Sulfamonomethoxine or other veterinary antibiotics.
-
EZ Cap™ Firefly Luciferase mRNA Workflows
2026-08-10
Build sensitive reporter assays and delivery screens with a Cap1-capped, poly(A)-optimized luciferase transcript. This guide connects practical handling, LNP comparison, cell-based translation studies, and in vivo bioluminescence imaging while highlighting where assay results can diverge.
-
Firefly Luciferase mRNA: From Signal to Translation
2026-08-09
A translational framework for using Firefly Luciferase mRNA to connect cap chemistry, nucleotide modification, delivery performance, and functional validation. The article explains how 5-moUTP modified mRNA can support more informative reporter workflows while clarifying the limits of extrapolating bioluminescence data to therapeutic mRNA programs.
-
EZ Cap Cy5 Firefly Luciferase mRNA for Dual Tracking
2026-08-08
Discover how EZ Cap Cy5 Firefly Luciferase mRNA separates delivery, intracellular trafficking, and protein production in one experiment. This guide combines Cap1 and 5-moUTP modified mRNA biology with evidence-based lipoplex design and practical interpretation of dual reporter data.
-
CUDC-907: Practical Dual PI3K/HDAC Workflow
2026-08-07
CUDC-907 provides a research tool for studying coordinated PI3K and HDAC pathway modulation in controlled cancer cell assays. This guide covers formulation, starting conditions, pathway and apoptosis readouts, and quality control, while emphasizing that the compound is for scientific research only and is not validated for diagnostic, clinical, or therapeutic use.
-
Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl
2026-08-07
Degarelix acetate empowers prostate cancer research and hormone pathway studies with rapid, selective GnRH receptor blockade. This guide outlines advanced protocols, troubleshooting strategies, and experimental enhancements for maximizing data quality and translational value.
-
GSTA1 Drives Glutathione Loss in α-Amanitin Hepatotoxicity
2026-08-06
This study reveals a paradoxical role for hepatic GSTA1 in α-amanitin-induced liver injury, demonstrating that its upregulation accelerates glutathione depletion and oxidative stress. The findings identify GSTA1 as a key driver of hepatotoxicity and suggest new research directions for targeting redox pathways in acute liver injury.